Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy

Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy

The humanised anti-CD20 antibody (Ab) rituximab (RTX) has significantly improved the prognosis of B cell non-Hodgkin’s lymphomas (BNHL). However, major challenges remain: a) RTX is often used with toxic chemotherapy that not only causes serious side effects but may also compromise RTX activity and h...

Full description

Bibliographic Details
Main Author: Xinjian Chen
Format: Article
Language:English
Published: European Medical Journal 2018-08-01
Series:European Medical Journal Hematology
Subjects:
direct cytotoxicity and necroptosis
graphene oxide (go)
oxidative stress
rituximab (rtx)
Online Access:https://www.emjreviews.com/hematology/article/making-rituximab-directly-cytotoxic-for-substantial-improvement-in-therapeutic-efficacy/

Internet

https://www.emjreviews.com/hematology/article/making-rituximab-directly-cytotoxic-for-substantial-improvement-in-therapeutic-efficacy/

Similar Items